20,26 €
Deine Einschätzung
Intellia Therapeutics Inc Aktie
Was spricht für und gegen Intellia Therapeutics Inc in den nächsten Jahren?
Pro
Kontra
Rendite von Intellia Therapeutics Inc im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Intellia Therapeutics Inc | 3,01 % | 10,32 % | -1,36 % | -38,18 % | -30,02 % | -84,87 % | 51,31 % |
Chromadex Corp | 5,96 % | 6,67 % | 8,11 % | 138,81 % | 142,42 % | -39,05 % | -13,27 % |
Organovo Holdings Inc. | -4,12 % | -5,17 % | -10,53 % | -62,07 % | -55,26 % | -92,92 % | -90,87 % |
Polynovo Ltd | -1,30 % | 6,29 % | 1,33 % | 97,40 % | 52,76 % | 24,59 % | 11,31 % |
Kommentare
News
The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger
Intellia Therapeutics (NASDAQ: NTLA) just published some new data that suggests the company has what it takes to continue being a leader in the gene editing space. While there's still a lot of work
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
Cathie Wood is known for two things: picking out innovators that will go on to score a win over the long run, and getting in on these stocks at a great price. The founder and chief executive officer
These 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right Now
On June 2, Intellia Therapeutics' (NASDAQ: NTLA) CEO John Leonard remarked on the biotech's progress with one of its early-stage clinical programs called NTLA-2002, uttering two very important words